These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29722587)

  • 1. The preclinical discovery and development of cariprazine for the treatment of schizophrenia.
    Wesołowska A; Partyka A; Jastrzębska-Więsek M; Kołaczkowski M
    Expert Opin Drug Discov; 2018 Aug; 13(8):779-790. PubMed ID: 29722587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
    Nakamura T; Kubota T; Iwakaji A; Imada M; Kapás M; Morio Y
    Drug Des Devel Ther; 2016; 10():327-38. PubMed ID: 26834462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
    Choi YK; Adham N; Kiss B; Gyertyán I; Tarazi FI
    CNS Spectr; 2017 Dec; 22(6):484-494. PubMed ID: 28059046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
    Saraf G; Pinto JV; Yatham LN
    Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
    [No Abstract]   [Full Text] [Related]  

  • 13. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
    Patel A; Patel A; Patel D; Patel K; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine for the Treatment of Bipolar Disorder.
    Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preclinical discovery and development of paliperidone for the treatment of schizophrenia.
    Wesołowska A; Jastrzębska-Więsek M; Cios A; Partyka A
    Expert Opin Drug Discov; 2020 Mar; 15(3):279-292. PubMed ID: 31661992
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania.
    Periclou A; Willavize S; Jaworowicz D; Passarell J; Carrothers T; Ghahramani P; Durgam S; Earley W; Kapás M; Khariton T
    Clin Transl Sci; 2020 Mar; 13(2):362-371. PubMed ID: 31664765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.